Caris Life Sciences Launches Caris Target Now™ Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
2
pages
English
Documents
Le téléchargement nécessite un accès à la bibliothèque YouScribe Tout savoir sur nos offres
2
pages
English
Documents
Le téléchargement nécessite un accès à la bibliothèque YouScribe Tout savoir sur nos offres
Publié par
Langue
English
Caris Life Sciences Launches Caris Target Now™ Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary PR Newswire IRVING, Texas, June 26, 2012 - Enhanced Molecular Profiling Service Now Includes More Biomarker Analysis Options, Faster Turnaround Time, and Clinical Trial Matching IRVING, Texas, June 26, 2012 /PRNewswire/-- Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now™ Select, an advanced, evidence- based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the original Caris Target Now comprehensive molecular profiling service offering for all solid tumors. "This latest effort by Caris is another significant step in what I call health improvement, while at the same time fulfilling on the promise of personalized medicine," said David D. Halbert, Chairman and CEO, Caris Life Sciences. "With these enhancements, we believe we can prolong the lives of patients and improve outcomes, while also lowering costs to the healthcare system." Caris Target Now Select incorporates updated, evidence-based technology platforms to determine the genomic information unique to a patient's tumor based on the presence of relevant biomarkers.
Voir
Publié par
Langue
English
Caris Life Sciences Launches Caris Target
Now™ Select for NSCLC, Melanoma, and
Cancers of the Breast, Colon, and Ovary
PR Newswire
IRVING, Texas, June 26, 2012
- Enhanced Molecular Profiling Service Now Includes More Biomarker
Analysis Options, Faster Turnaround Time, and Clinical Trial Matching
IRVING, Texas
,
June 26, 2012
/PRNewswire/
--
Caris Life Sciences®, a leading
biosciences company focused on enabling precise and personalized healthcare
through molecular profiling and blood-based diagnostic services, today
announced the launch of Caris Target Now™
Select
, an advanced, evidence-
based molecular profiling service for patients with non-small cell lung cancer
(NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition,
the company has enhanced the original Caris Target Now comprehensive
molecular profiling service offering for all solid tumors.
"This latest effort by Caris is another significant step in what I call health
improvement, while at the same time fulfilling on the promise of personalized
medicine," said David D. Halbert, Chairman and CEO, Caris Life Sciences. "With
these enhancements, we believe we can prolong the lives of patients and
improve outcomes, while also lowering costs to the healthcare system."
Caris Target Now
Select
incorporates updated, evidence-based technology
platforms to determine the genomic information unique to a patient's tumor
based on the presence of relevant biomarkers. In addition to providing focused
biomarker profiles designed for earlier-stage cancer patients, it offers the
advantages of known "on-Compendium-only" drug associations, faster
turnaround time, the capability to derive meaningful results from smaller tissue
samples, up to 30 reported biomarkers per patient (depending on tumor type),
and – for the first time –
Clinical Trials Connector
™, a service that enables
biomarker-specific clinical trial matching.
"Caris Target Now
Select
is an important new tool to assist physicians in
choosing among standard drug choices earlier in the course of treatment,
where molecular profiling can have the largest benefit to patient care," said
Tom Spalding, Oncology Senior Vice President and Group Head, Caris Life
Sciences. "In addition, the new Clinical Trials Connector uncovers even more
possibilities by linking patients to open and enrolling clinical trials based upon
their individual biomarker status."
Using the strongest clinical evidence, Caris Target Now
Select
highlights known
therapeutic associations with appropriate, tumor-specific treatments for the
five target tumor types, as identified in the National Comprehensive Cancer
Network Drug & Biologics Compendium™[1]. In addition, the newly enhanced
version of Caris' original molecular profiling service (now renamed Caris Target
Now
Comprehensive
) provides both on- and off-Compendium therapeutic
associations for all solid tumors, across a wide range of evidence.
"Caris Target Now
Select
is an evidence-based molecular profiling service that
can help both earlier-stage and later-stage cancer patients, as it employs the
most relevant biomarkers and technologies to help decode a patient's tumor,"
said Sandeep Reddy, MD, Clinical Professor of Medicine at the David Geffen
School of Medicine at the University of California, Los Angeles (UCLA) and
Senior Medical Director at Caris. "This service allows physicians to augment
their years of experience with advanced theranostic resources, further
personalizing cancer care based on the expression status of specific
biomarkers."
Through analysis with multiple, highly integrated technology platforms such as
immunohistochemistry (IHC), fluorescence
in situ
hybridization (FISH),
polymerase chain reaction (PCR), and DNA sequencing, both the Caris Target
Now
Select
and
Comprehensive
services provide vital information that may be
useful to oncologists in individualizing therapeutic regimens for cancer patients.
By utilizing the most relevant, evidence-based molecular profiling technologies
to determine the biomarkers unique to a patient's tumor, and performing an
extensive review of clinical literature correlating biomarkers to drug response,
Caris Target Now
Select
can help illuminate the benefit (or lack thereof) of
specific agents, and may reveal appropriate treatments not previously
considered.
Both services can be requested for cancer patients by physicians seeking to
utilize biomarker analysis to inform therapeutic decision-making. For more
information, visit www.caristargetnow.com.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and
delivering innovative molecular diagnostic, prognostic, and theranostic services.
The company's evidence-based molecular profiling service, Caris Target Now™,
matches molecular data generated from a patient's tumor with biomarker/drug
associations derived from the world's leading clinical cancer literature. Caris
Target Now uses the most advanced and clinically relevant technologies to
provide physicians with information to aid in the selection of personalized
cancer treatments more likely to work for each patient. Caris is also developing
a series of blood tests based on the company's patented Carisome™ platform
— a proprietary, blood-based testing technology for diagnosis, prognosis, and
theranosis of cancer and other complex diseases. Through the precise and
personalized information provided by technologies like Caris Target Now and
Carisome, the company believes that the quality of healthcare can be
dramatically improved, while also significantly reducing costs. Headquartered in
the
Dallas
metroplex, Caris Life Sciences offers services throughout
the United
States
,
Europe
, and other international markets. To learn more, please visit
www.carislifesciences.com or www.caristargetnow.com.
[1] About the NCCN Drugs & Biologics Compendium (NCCN Compendium™).
Fort Washington, PA
: National Comprehensive Cancer Network; 2012. Available
at: http://www.nccn.org/professionals/drug_compendium/content/about.asp.
Accessed
May 2, 2012
.
